PROS1 and infection: For example, Novavax has advanced and generated immunogenic virus-like NPs based on recombinant expression of the S-protein, while Clover Biopharmaceuticals is producing a subunit vaccine containing a trimerized SARS-CoV-2 S-protein utilizing their patented Trimer-Tag® method, though some full-length S-proteins for SARS as well cause enhanced infection and eosinophilic penetration [5, 121] (Table 2).